放射性核素~(89)Sr联合唑来磷酸治疗乳腺癌多发骨转移的疗效及不良反应观察
|
摘要
目的:了解乳腺癌多发骨转移患者接受放射性核素~(89)Sr、唑来膦酸联合治疗方案对病情的改善作用以及安全性。方法:选本院2014年至2018年收治乳腺癌多发骨转移患者为分析对象,从中选取60例,数字编序并随机进行分组,每组20例,分别为A组(单纯放射性核素~(89)Sr治疗)、B组(单纯唑来膦酸治疗)、C组(放射性核素~(89)Sr联合唑来膦酸双向治疗)。对患者资料对比分析后归纳双向联合治疗方案对于乳腺癌多发骨转移患者的临床价值。结果:在骨痛控制方面,C组患者有效率显著优于A组、B组,组间数据差异存在统计学意义(P<0.05);在病灶控制方面,C组患者有效率显著优于A组、B组,组间数据差异存在统计学意义(P<0.05);各组患者均无出现严重不良反应,不适症状在对症处理后消失,发生率无统计学意义(P>0.05)。结论:为乳腺癌多发骨转移患者采取放射性核素89Sr联合唑来膦酸方案进行干预无论在缓解骨痛、控制病灶方面均有突出价值,且联合方案不会提高不良反应发生率,对疗程的进行无负面影响,值得推广。
Objectivee To investigate the improvement and safety of combined radionuclide 89 Sr and zoledronic acid treatment regimens in patients with multiple bone metastases from breast cancer.t regimens in patients with multiple bone metastases from breast cancer.Methods Methods The patients selected for breast cancer with multiple bone metastases from 2014 to 2018 were selected as the analysis subjects.Sixty patients were selected from the study.The numbers were serialized and randomly divided into groups.There were 20 patients in each group,group A(radioactive radionuclide alone).89 Sr treatment),group B(only zoledronic acid treatment),group C(radioactive nuclide 89 Sr combined with zoledronic acid bidirectional treatment).The comparative analysis of patient data after the induction of two-way combination therapy for patients with multiple bone metastases in breast cancer clinical value.y combination therapy for patients with multiple bone metastases in breast cancer clinical value.Results Results In terms of bone pain control,the effective rate of group C was significantly better than that of group A and group B,and the difference between groups was statistically significant(P<0.05).In terms of lesion control,the effective rate of group C was significantly better than that of group A and group B,and the difference between groups was statistically significant(P<0.05).No serious adverse reactions were observed in all groups.The discomfort symptoms disappeared after symptomatic treatment,and the incidence was not statistically significant(P>0.05).Conclusion Conclusion The intervention of radionuclide 89 Sr combined with zoledronic acid for patients with multiple bone metastases in breast cancer has significant value in relieving bone pain and controlling lesions,There is no negative effect and it is worth promoting.
Objectivee To investigate the improvement and safety of combined radionuclide 89 Sr and zoledronic acid treatment regimens in patients with multiple bone metastases from breast cancer.t regimens in patients with multiple bone metastases from breast cancer.Methods Methods The patients selected for breast cancer with multiple bone metastases from 2014 to 2018 were selected as the analysis subjects.Sixty patients were selected from the study.The numbers were serialized and randomly divided into groups.There were 20 patients in each group,group A(radioactive radionuclide alone).89 Sr treatment),group B(only zoledronic acid treatment),group C(radioactive nuclide 89 Sr combined with zoledronic acid bidirectional treatment).The comparative analysis of patient data after the induction of two-way combination therapy for patients with multiple bone metastases in breast cancer clinical value.y combination therapy for patients with multiple bone metastases in breast cancer clinical value.Results Results In terms of bone pain control,the effective rate of group C was significantly better than that of group A and group B,and the difference between groups was statistically significant(P<0.05).In terms of lesion control,the effective rate of group C was significantly better than that of group A and group B,and the difference between groups was statistically significant(P<0.05).No serious adverse reactions were observed in all groups.The discomfort symptoms disappeared after symptomatic treatment,and the incidence was not statistically significant(P>0.05).Conclusion Conclusion The intervention of radionuclide 89 Sr combined with zoledronic acid for patients with multiple bone metastases in breast cancer has significant value in relieving bone pain and controlling lesions,There is no negative effect and it is worth promoting.
引文
[1]芦亚洲.放射性核素89Sr与唑来磷酸联合治疗乳腺癌多发骨转移的疗效观察[J].临床医药文献电子杂志,2016,3(20):3954-3955.
[2]李敏,陆粤就,黄文添.唑来膦酸联合希罗达治疗乳腺癌多发性骨转移的临床疗效[J].今日药学,2017,27(9):629-631.
[3]余悦,宋晓良,郝婷婷,等.SPECT结合SPECT/CT骨显像对乳腺癌骨转移的诊断价值[J].医学影像学杂志,2016,26(4):637-640.
[4]王乐园.唑来膦酸联合同期化疗治疗乳腺癌骨转移的疗效[J].中外医疗,2016,35(30):150-152.
[5]赵丹丹,李春雨.89Sr Cl2联合99Tc-MDP治疗乳腺癌骨转移骨痛的疗效观察[J].中国现代普通外科进展,2017,20(2):137-139.
[2]李敏,陆粤就,黄文添.唑来膦酸联合希罗达治疗乳腺癌多发性骨转移的临床疗效[J].今日药学,2017,27(9):629-631.
[3]余悦,宋晓良,郝婷婷,等.SPECT结合SPECT/CT骨显像对乳腺癌骨转移的诊断价值[J].医学影像学杂志,2016,26(4):637-640.
[4]王乐园.唑来膦酸联合同期化疗治疗乳腺癌骨转移的疗效[J].中外医疗,2016,35(30):150-152.
[5]赵丹丹,李春雨.89Sr Cl2联合99Tc-MDP治疗乳腺癌骨转移骨痛的疗效观察[J].中国现代普通外科进展,2017,20(2):137-139.